Skip to main content

Table 1 Baseline Patient characteristics and treatment

From: A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis

Characteristic

Overall, n(%)

Groups

p-value

TOR

TAM

Age

   

0.053

  < 40

12(13.0)

3

9

 

  ≥ 40

80(87.0)

44

36

 

BMI

   

0.880

  < 24

73(79.3)

37

36

 

  ≥ 24

19(20.7)

10

9

 

Surgery

   

0.273

 Mastectomy

54(58.7)

25

29

 

 BCS

38(41.3)

22

16

 

Pathology

   

0.890

 IDC

72(78.3)

37

35

 

 DCIS

7(7.6)

4

3

 

 Others

13(14.1)

6

7

 

Tumors

   

0.717

  ≤ 2.0 cm

67(72.8)

35

32

 

  > 2.0 cm

25(27.2)

12

13

 

Nodes status

   

0.830

 Negative

79(85.9)

40

39

 

 Positive

13(14.1)

7

6

 

Grade

   

0.655

 I

15(16.3)

9

6

 

 II

47(51.1)

25

22

 

 III

11(12.0)

4

7

 

 NA

19(20.7)

9

10

 

ER

   

0.430

  ≥ 50%

86(93.5)

43

43

 

  < 50%

6(6.5)

4

2

 

PR

   

0.399

  ≥ 20%

69(75)

37

32

 

  < 20%

23(25)

10

13

 

HER-2

   

0.430

 positive

6(6.5)

4

2

 

 negative

86(93.5)

43

43

 

Subtype

   

0.164

 Luminal A like

40(43.5)

24

16

 

 Luminal B HER2 negative

46(50.0)

19

27

 

 Luminal B HER2 positive

6(6.5)

4

2

 

Ki67

   

0.554

  < 14%

58(63.0)

31

27

 

  ≥ 14%

34(37.0)

16

18

 

Chemotherapy

   

0.709

 Yes

33(35.9)

16

17

 

 No

59(64.1)

31

28

 

Radiotherapy

   

0.828

 Yes

44(47.8)

23

21

 

 No

48(52.2)

24

24

 

Trastuzumab

   

0.328

 Yes

4(4.3)

3

1

 

 No

88(95.7)

44

44

 
  1. Abbreviations: BMI Body Mass Index, IDC Invasive ductal carcinoma, DCIS Ductal carcinoma in situ, NA Not available, BCS Breast conserving surgery, ER Estrogen receptor, PR Progestrone receptor, TAM Tamoxifen, TOR Toremifene
  2. *p < 0.05 was considered statistically significant
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us